不同HDL—C水平控制方案治疗冠心病患者疗效观察

Efficacy observation of different HDL-C level control scheme in the treatment of patients with CAD

目的探讨不同高密度脂蛋白胆固醇（HDL-C）水平控制方案治疗冠心病（CAD）患者临床效果、安全性及预后影响。方法选取121例CAD患者为研究对象，随机分成非药物组（A组，n=61）和综合组（B组，n=60）两组。对比治疗前后HDL—C水平变化情况，记录其治疗后不良反应发生率，对比其生活质量。结果①两组患者治疗后HDL—C水平均较治疗前明显提升，其中B组提升幅度大于A组（P〈0．05）；②A组治疗后不良反应率为8．2％，B组为16．7％，两组比较差异未见统计学意义（P〉0．05）；③B组治疗后心绞痛改善程度明显高于A组（P〈0．01）。结论对冠心病患者采用运动干预、饮食调控、戒烟禁酒联合烟酸及他汀类降脂药物方案，疗效突出，毒副反应轻微，预后质量较高，值得临床推广。

Objective To investigate the clinical effect, safety and prognosis of different HDL-C level control scheme in the treatment of patients with CAD. Methods The 121 cases of CAD patients were chose as the research objects, and were randomly divided into non drug group （group A, n = 61 ） and combined group （group B, n =60）. HDL-C levels before and after treatment were compared, the incidence of adverse reaction and the quality of life was compared. Results The HDL-C levels improved significantly after treatment in both groups, the ascension of group B was greater than the group A （P 〈 0.05） ; ② After treatment, the adverse reaction rate was 8.2% in group A, and 16.7% in group B, there was no significant difference （P 〉 0.05 ） ; ③The degree of improvement in angina was higher in group B than that in group A （P 〈 0.01＇）. Conclusions In patients with cerebral vascular disease, exercise, diet control, smoking prohibition, with niacin and statin lipid-lowering drugs, has obvious curative effect and little adverse reaction, the prognosis has high quality, so is worthy the clinical promotion.